Study Details Decline in Febuxostat Use Following Addition of Boxed Warning by FDA

Study Details Decline in Febuxostat Use Following Addition of Boxed Warning by FDA

A new study is providing clinicians with a breakdown of the real-world impact of the 2019 labeling changes to febuxostat (Uloric) following the U.S. Food and Drug Administration (FDA)’s addition of a boxed warning to packaging for the treatment of gout. An analysis of data from the IQVIA PharMetrics Plus database and the Optum Research …

Study Details Decline in Febuxostat Use Following Addition of Boxed Warning by FDA Read More »